OncoMatch/Clinical Trials/NCT07313241
Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)
Is NCT07313241 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Androgen Deprivation Therapy (ADT) for prostate cancer.
Treatment: Androgen Deprivation Therapy (ADT) — This Phase II, single arm study evaluates a PSA-response-adapted approach to salvage radiotherapy after radical prostatectomy for prostate cancer. All participants will receive hypo-fractionated stereotactic radiotherapy to the prostate fossa. At 5 weeks, biochemical response will be assessed. responders will proceed to observation, while non responders will receive sequential pelvic nodal radiotherapy and 4 months of androgen deprivation therapy (ADT). The study aims to determine whether this response base approach achieves non inferior 2 year freedom from progression compared with historical outcomes using routine pelvic nodal radiotherapy and ADT in all patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: prostatectomy — localized
treated with prostatectomy in the localized setting within 10 years
Cannot have received: androgen deprivation therapy
Exception: ≤ 3 months allowed with ≥30 day washout and testosterone >50ng/mL
Prior androgen deprivation therapy (ADT) > 3 months... For shorter courses of either, at least 30 day 'wash out' period is required with confirmation of resolved castration of testosterone to >50ng/mL.
Cannot have received: anti-androgen therapy
Exception: ≤ 30 days allowed with ≥30 day washout and testosterone >50ng/mL
anti-androgen therapy (AAT) of > 30 days. For shorter courses of either, at least 30 day 'wash out' period is required with confirmation of resolved castration of testosterone to >50ng/mL.
Cannot have received: testosterone replacement therapy
Exception: must be stopped with demonstration of detectable PSA ≥0.05ng/mL and non-castrate testosterone >50ng/mL after 14 days of TRT cessation
Ongoing testosterone replacement therapy (TRT) with refusal to discontinue (must be stopped with demonstration of detectable PSA ≥0.05ng/mL and non-castrate testosterone >50ng/mL after 14 days of TRT cessation)
Cannot have received: pelvic radiotherapy
Prior pelvic radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UT Southwestern Medical Center-Dallas · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify